-$0.29 Earnings Per Share Expected for Xencor, Inc. (XNCR) This Quarter
Wall Street analysts expect that Xencor, Inc. (NASDAQ:XNCR) will post ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Xencor’s earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.32). Xencor posted earnings per share of ($0.20) during the same quarter last year, which indicates a negative year-over-year growth rate of 45%. The company is expected to issue its next earnings results on Wednesday, November 1st.
On average, analysts expect that Xencor will report full-year earnings of ($1.07) per share for the current year, with EPS estimates ranging from ($1.25) to ($0.94). For the next fiscal year, analysts expect that the firm will post earnings of ($1.63) per share, with EPS estimates ranging from ($2.02) to ($1.15). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Xencor.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.10. The business had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%.
Several analysts recently weighed in on XNCR shares. Canaccord Genuity restated a “buy” rating and issued a $36.00 price target on shares of Xencor in a research note on Tuesday, August 8th. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Wedbush reiterated an “outperform” rating and set a $29.00 price objective on shares of Xencor in a research note on Friday, June 16th. Finally, BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $29.33.
COPYRIGHT VIOLATION NOTICE: “-$0.29 Earnings Per Share Expected for Xencor, Inc. (XNCR) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/04/0-29-earnings-per-share-expected-for-xencor-inc-xncr-this-quarter.html.
Xencor (NASDAQ:XNCR) traded up 3.57% during mid-day trading on Wednesday, hitting $24.67. 159,039 shares of the stock traded hands. The firm’s market cap is $1.16 billion. Xencor has a 52-week low of $18.45 and a 52-week high of $29.38. The firm’s 50-day moving average is $21.71 and its 200 day moving average is $22.43.
In other news, major shareholder John S. Stafford III acquired 41,016 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average cost of $19.69 per share, for a total transaction of $807,605.04. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder John S. Stafford III acquired 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average price of $20.96 per share, with a total value of $524,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 215,551 shares of company stock worth $4,386,916. Corporate insiders own 4.14% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in XNCR. Public Employees Retirement System of Ohio boosted its stake in Xencor by 17.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 25,707 shares of the biopharmaceutical company’s stock valued at $543,000 after purchasing an additional 3,844 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Xencor by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,771 shares of the biopharmaceutical company’s stock worth $629,000 after purchasing an additional 1,673 shares in the last quarter. State Street Corp increased its holdings in shares of Xencor by 11.1% in the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after purchasing an additional 110,474 shares in the last quarter. Maverick Capital Ltd. increased its holdings in shares of Xencor by 39.3% in the 2nd quarter. Maverick Capital Ltd. now owns 157,928 shares of the biopharmaceutical company’s stock worth $3,334,000 after purchasing an additional 44,593 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Xencor by 2.3% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock worth $492,000 after purchasing an additional 521 shares in the last quarter. 76.92% of the stock is currently owned by institutional investors and hedge funds.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.